magAssist Included in List of 2022 Potential Unicorn Companies in Jiangsu Province

On December 9, 2022, the Jiangsu Productivity Promotion Center announced the evaluation results of this year’s provincial unicorn companies, potential unicorn companies and gazelle companies. magAssist was recognized as a potential unicorn company in Jiangsu Province for the second consecutive year by virtue of its technological innovation in the field of advanced medical devices, making it a benchmark for hard-tech companies in the medical field.


magAssist Included in List of 2022 Potential Unicorn Companies in Jiangsu Province



Listed below are the selected enterprises in the Suzhou New District:


magAssist Included in List of 2022 Potential Unicorn Companies in Jiangsu Province


“Unicorn companies focus on key areas and critical aspects of the industry, and make consistent efforts to strengthen original innovation in a bid to make technological breakthroughs and continuously enhance their core competitiveness,” pointed out Zhiqiang Zhao, Director of the Jiangsu Productivity Promotion Center. magAssist targets state-of-the-art technologies for artificial organs. In the context of promoting the national strategies and relying on the unique advantages of the Suzhou New District’s comprehensive medical industry system, excellent business environment and wealth of talent resources, magAssist has continually achieved accelerated growth since its establishment five years ago. The MoyoAssist® Extracorporeal Ventricular Assist Device developed by magAssist is the first model of its kind in China and has been successfully implemented in clinical practice. The Minimally Invasive Percutaneous Ventricular Assist Device, Next-generation extracorporeal Membrane Oxygenation System (ECMO), Organ Warm Blood Transfer Platform and various other product lines are advancing in tandem, making magAssist a pioneer in the field of multi-organ life support. magAssist will consistently focus on researching core life support technologies in order to inject greater momentum into accelerating the import substitution of advanced medical devices.

E-mail     Share on Linkedin     Share on Facebook
Recommendation